These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35741048)

  • 1. T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies.
    Pulvirenti F; Di Cecca S; Sinibaldi M; Piano Mortari E; Terreri S; Albano C; Guercio M; Sculco E; Milito C; Ferrari S; Locatelli F; Quintarelli C; Carsetti R; Quinti I
    Cells; 2022 Jun; 11(12):. PubMed ID: 35741048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
    Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functionally impaired antibody response to BNT162b2 booster vaccination in CVID IgG responders.
    Sauerwein KMT; Geier CB; Stemberger RF; Rossmanith R; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
    J Allergy Clin Immunol; 2023 Apr; 151(4):922-925. PubMed ID: 36463978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best.
    Salinas AF; Mortari EP; Terreri S; Quintarelli C; Pulvirenti F; Di Cecca S; Guercio M; Milito C; Bonanni L; Auria S; Romaggioli L; Cusano G; Albano C; Zaffina S; Perno CF; Spadaro G; Locatelli F; Carsetti R; Quinti I
    J Clin Immunol; 2021 Nov; 41(8):1709-1722. PubMed ID: 34669144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen-Specific CD4
    Sauerwein KMT; Geier CB; Stemberger RF; Akyaman H; Illes P; Fischer MB; Eibl MM; Walter JE; Wolf HM
    Front Immunol; 2022; 13():827048. PubMed ID: 35237272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated CD21
    Bergman P; Wullimann D; Gao Y; Wahren Borgström E; Norlin AC; Lind Enoksson S; Aleman S; Ljunggren HG; Buggert M; Smith CIE
    J Clin Immunol; 2022 May; 42(4):716-727. PubMed ID: 35290571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency.
    Goda V; Kriván G; Kulcsár A; Gönczi M; Tasnády S; Matula Z; Nagy G; Bekő G; Horváth M; Uher F; Szekanecz Z; Vályi-Nagy I
    Front Immunol; 2022; 13():907125. PubMed ID: 35784359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency.
    Barmettler S; DiGiacomo DV; Yang NJ; Lam T; Naranbhai V; Dighe AS; Burke KE; Blumenthal KG; Ling M; Hesterberg PE; Saff RR; MacLean J; Ofoman O; Berrios C; St Denis KJ; Lam EC; Gregory D; Iafrate AJ; Poznansky M; Lee H; Balazs A; Pillai S; Farmer JR
    J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1622-1634.e4. PubMed ID: 35381395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
    Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
    Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Immune Response to SARS-CoV-2 Vaccination: Insights Learned From Adult Patients With Common Variable Immune Deficiency.
    Quinti I; Locatelli F; Carsetti R
    Front Immunol; 2021; 12():815404. PubMed ID: 35126372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies.
    Mizera D; Dziedzic R; Drynda A; Gradzikiewicz A; Jakieła B; Celińska-Löwenhoff M; Padjas A; Matyja-Bednarczyk A; Zaręba L; Bazan-Socha S
    Front Immunol; 2023; 14():1275892. PubMed ID: 37901210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency.
    Shin JJ; Par-Young J; Unlu S; McNamara A; Park HJ; Shin MS; Gee RJ; Doyle H; Afinogenova Y; Zidan E; Kwah J; Russo A; Mamula M; Hsu FI; Catanzaro J; Racke M; Bucala R; Wilen C; Kang I
    J Clin Immunol; 2022 Aug; 42(6):1137-1150. PubMed ID: 35713752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 Severity, Cardiological Outcome, and Immunogenicity of mRNA Vaccine on Adult Patients With 22q11.2 DS.
    Pulvirenti F; Mortari EP; Putotto C; Terreri S; Fernandez Salinas A; Cinicola BL; Cimini E; Di Napoli G; Sculco E; Milito C; Versacci P; Agrati C; Marino B; Carsetti R; Quinti I
    J Allergy Clin Immunol Pract; 2023 Jan; 11(1):292-305.e2. PubMed ID: 36280136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single dose of COVID-19 vaccine induces a strong T cell and B cell response in healthcare professionals recovered from SARS-CoV-2 infection.
    Laranjeira P; Rodrigues T; Silva A; Barbosa P; Reis T; Lopes C; Pinho A; Silva S; Silva I; Carvalho A; Pacheco V; Rodrigues F; Araújo L; Antunes I; Paiva A
    Clin Exp Med; 2023 Jun; 23(2):529-537. PubMed ID: 35190936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior SARS-CoV-2 Infection Enhances Initial mRNA Vaccine Response with a Lower Impact on Long-Term Immunity.
    Silva-Moraes V; Souquette A; Sautto GA; Paciello I; Antonelli G; Andreano E; Rappuoli R; Teixeira-Carvalho A; Ross TM
    Immunohorizons; 2023 Oct; 7(10):635-651. PubMed ID: 37819998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
    Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
    Front Immunol; 2021; 12():778679. PubMed ID: 34868051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
    Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
    Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.